Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients (2021)
- Authors:
- Autor USP: TRAINA, FABÍOLA - FMRP
- Unidade: FMRP
- DOI: 10.1182/blood-2021-151077
- Subjects: DOENÇAS INFECCIOSAS; FEBRE; DENGUE; ESTUDOS SOROEPIDEMIOLÓGICOS; RESÍDUOS SÓLIDOS
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2021
- Source:
- Conference titles: ASH Annual Meeting
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
CAMPOS, Paula de Melo et al. Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-151077. Acesso em: 27 jan. 2026. , 2021 -
APA
Campos, P. de M., Pagnano, K. B., Mancuso, R. I., Della Via, F. I., Tinoco, Â. C., Mendonça, G. R. A., et al. (2021). Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2021-151077 -
NLM
Campos P de M, Pagnano KB, Mancuso RI, Della Via FI, Tinoco ÂC, Mendonça GRA, Freitas LLL, Traina F, Saad STO. Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients [Internet]. Blood. 2021 ; 138 2584-2585.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1182/blood-2021-151077 -
Vancouver
Campos P de M, Pagnano KB, Mancuso RI, Della Via FI, Tinoco ÂC, Mendonça GRA, Freitas LLL, Traina F, Saad STO. Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients [Internet]. Blood. 2021 ; 138 2584-2585.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1182/blood-2021-151077 - Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia
- IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients
- Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells
- Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome
- STMN1 (stathmin 1)
- Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms
- Differential profile of PIP4K2A expression in hematological malignancies
- FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation
- Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
- MDR-1 and GST polymorphisms are involved in myelodysplasia progression
Informações sobre o DOI: 10.1182/blood-2021-151077 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003237465.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
